A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP),
and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied
IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.